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ABSTRACT
The ability to develop a comprehensive panel of treatment predicting factors 
would significantly improve our ability to stratify patients for cytotoxic or targeted 
therapies, and prevent patients receiving ineffective treatments. We have investigated 
if a recently developed genome-wide haploid genetic screen can be used to reveal the 
critical mediators of response to anticancer therapy. Pancreatic cancer is known to be 
highly resistant to systemic therapy. Recently epigenetic changes have been shown 
to be a key determinant in the maintenance of subpopulations of cancer cells with 
high-level resistance to cytotoxic therapy. We show that in human pancreatic cancer 
cell lines, treatment with the potent class I histone deacetylase inhibitor, entinostat, 
synergistically enhances gemcitabine-induced inhibition of cell proliferation and 
apoptosis. Using a genome-wide haploid genetic screen, we identified deoxycytidine 
kinase (DCK) as one of the genes with the highest degree of insertional enrichment 
following treatment with gemcitabine and entinostat; DCK is already known to be 
the rate-limiting activating enzyme for gemcitabine. Immunoblotting confirmed loss 
of DCK protein expression in the resistant KBM7 cells. CRISPR/Cas-9 inactivation of 
DCK in pancreatic cancer cell lines resulted in resistance to gemcitabine alone and 
in combination with entinostat. We have identified gemcitabine and entinostat as a 
potential new combination therapy in pancreatic cancer, and in this proof-of-principle 
study we have demonstrated that a recently developed haploid genetic screen can 
be used as a novel approach to identify the critical genes that determine treatment 
response.
INTRODUCTION
Loss-of-function genetic screens in model 
organisms such as yeast, have helped to elucidate many 
biological processes, but such large-scale gene disruption 
has not previously been possible in human cells due to 
the difficulty in generating bi-allelic mutations in diploid 
cells. While the development of siRNA and shRNA 
libraries have made it possible to perform analogous loss-
of-function genetic screens in mammalian cells, RNA 
interference-based screens suffer from off-target effects, 
and do not always succeed in completely eliminating gene 
expression. This problem has recently been circumvented 
following the isolation of a near-haploid human cell line, 
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a derivative of the KBM7 chronic myeloid leukaemia line 
which is haploid for all chromosomes except chromosome 
8 [1]. This has enabled the development of a genome-
wide loss-of-function screen in human cells, based on 
insertional mutagenesis of these near haploid cells with 
a gene-trap retrovirus [2, 3]. While this screen has some 
drawbacks in that it will fail to detect genes essential for 
cell survival or those that function redundantly, genome-
wide haploid screening of the KBM7 cell line has been 
successfully used to identify the host gene products 
necessary for the cytotoxic effects of several viruses and 
microbial toxins [2, 4, 5].
We hypothesised that this genome-wide haploid 
genetic screen could also be used to reveal the critical 
mediators of response to anticancer therapies. The ability 
to develop a comprehensive panel of treatment predicting 
factors would help improve our ability to stratify patients 
for cytotoxic or targeted therapies, and prevent patients 
from receiving ineffective treatments. We thus initiated 
this proof-of-principle study in pancreatic cancer.
Pancreatic cancer is associated with an extremely 
poor prognosis and ranks as the 4th most common cause 
of cancer-related death in the Western world [6]. This 
poor prognosis has been attributed to the fact that most 
patients present with advanced disease and also to the 
fact that pancreatic cancer is highly resistant to systemic 
therapy. Single-agent gemcitabine was established as 
the standard treatment for advanced pancreatic cancer 
in 1997, but its benefit is modest with 1-year survival 
of just 20% for patients with metastatic disease [7]. 
Combination chemotherapy with FOLFIRINOX and 
nab-paclitaxel in combination with gemcitabine have 
both recently demonstrated improved survival in patients 
with metastatic pancreatic cancer [8, 9], but due to their 
significant toxicity, single agent gemcitabine remains the 
standard treatment for a significant proportion of patients 
with advanced pancreatic cancer. There thus remains 
an unmet need for more efficacious and better tolerated 
therapy.
The development of resistance to cytotoxic or 
targeted therapy in a cancer patient greatly limits 
the effectiveness of available anticancer therapies. 
A variety of mechanisms of resistance have been 
identified including enhanced drug metabolism, drug 
efflux from cancer cells and activation of alternative 
survival pathways [10]. These mechanisms are generally 
believed to reflect the existence of mutations that arise 
spontaneously at low frequency in tumour cells prior to 
treatment and are selected during treatment. However the 
high prevalence of drug resistance suggests the presence 
of nonmutational mechanisms. Recently dynamic 
chromatin modifications have been identified as a key 
determinant in the maintenance of subpopulations of 
cancer cells with high-level resistance to cytotoxic 
therapy, which can be reversed by histone deacetylase 
inhibitors [11].
In pancreatic cancer, several members of the 
histone deacetylase (HDAC) family have been reported 
to be overexpressed [12, 13, 14], which in turn have 
been associated with enhanced resistance to apoptosis, 
poor tumour differentiation and worse survival [13, 15]. 
Overexpression of class I HDACs has also been observed 
in desmoplastic stroma cells and inflammatory cells 
[13]. This is relevant because therapeutic resistance in 
pancreatic cancer is known to be due to a combination of 
cell intrinsic and extrinsic (stroma) resistance.
Several HDAC inhibitors have been reported 
to increase sensitivity to gemcitabine in vitro and 
in vivo [16–19], yet a randomised phase II trial failed to 
demonstrate any efficacy of the weak HDAC inhibitor CI-
994 combined with gemcitabine compared to gemcitabine 
alone [20]. However, it is now clear that in solid tumours, 
the potency of HDAC inhibitors is critical in determining 
efficacy; recently the first objective and durable responses 
in patients with solid tumours (patients with refractory 
advanced non-small cell lung cancer) were reported using 
azacytidine in combination with the potent class I HDAC 
inhibitor, entinostat, and it is now believed that failure of 
previous trials to demonstrate efficacy was due to the use 
of less potent HDAC inhibitors [21].
Here, we show that in pancreatic cancer cell lines, 
the potent class I HDAC inhibitor entinostat synergistically 
enhances sensitivity to gemcitabine, and we observed this 
effect in both gemcitabine-sensitive and gemcitabine-
resistant cell lines. We then performed a genome-wide 
haploid genetic screen to identify gene mutations that 
confer resistance to treatment with gemcitabine and 
entinostat. The deoxycytidine kinase (DCK) protein, 
which is already known to be important for gemcitabine 
activation, was identified as one of our top hits from 
this screen. We show that DCK is a critical determinant 
of sensitivity to treatment with gemcitabine alone or in 
combination with entinostat in pancreatic cancer cells, 
demonstrating the ability of this system to reveal the 
critical mediators of response to cancer therapeutics.
RESULTS
Entinostat inhibits cell proliferation and 
increases acetylation of histone H3 in pancreatic 
cancer cell lines
Prior to conducting combination studies, we first 
assessed the single agent antiproliferative activity of the 
potent class I HDAC inhibitor, entinostat, in pancreatic 
cancer cells; 6 human pancreatic cancer cell lines (PANC-1, 
MIA PaCa-2, BxPC-3, CFPAC-1, SUIT2 and SUIT2 Clone 
1) were treated with variable concentrations of entinostat (0-
100μM) for 72 hours and cell viability was assessed by XTT 
assays. Entinostat caused a dose-dependent decrease in cell 
proliferation and viability in all cell lines tested (Figure 1). 
This was associated with a dose-dependent increase in 
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histone H3 acetylation, with no effect on total histone H3 
protein levels (Figure 2), confirming that entinostat inhibits 
the deacetylation activity of the HDACs in pancreatic 
cancer cell lines.
As phase I studies of entinostat have already shown 
that at the maximum tolerated dose the peak plasma 
concentrations usually exceeds 75ng/mL (equivalent to 
~ 200μM), which is well above that required to induce 
significant growth inhibition in pancreatic cancer cells, we 
therefore proceeded with combination studies.
Entinostat enhances gemcitabine inhibition of 
cell proliferation in pancreatic cancer cell lines
Although several HDAC inhibitors have been 
reported to increase sensitivity to gemcitabine, this has 
not been demonstrated for entinostat. To investigate the 
effects of entinostat on gemcitabine sensitivity, 6 human 
pancreatic cancer cell lines (PANC-1, MIA PaCa-2, BxPC-
3, CFPAC-1, SUIT2 and SUIT 2 Clone 1) were treated 
with variable concentrations of entinostat (0-10μM) in 
addition to gemcitabine (0-10μM) for 72 hours and cell 
viability was assessed by XTT assays. Because previous 
studies have shown that pre-treatment with entinostat for 
24 hours yielded the most pronounced synergistic effects 
[22], we also tested pre-treatment with entinostat for 
24 hours followed by gemcitabine for 72 hours. Synergistic 
interactions were inferior (data not shown) thus all 
subsequent assays were performed with simultaneous drug 
treatments. Lower than IC50 concentrations of entinostat 
and gemcitabine were used in the combination studies as 
we wanted to assess the effect of using minimally effective 
Figure 1: Antiproliferative activity of entinostat. PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were 
plated at a density of 3-5x103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence 
of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values 
from triplicate wells from two independent experiments ±SE.
Figure 2: Effects of entinostat on histone H3 acetylation. PANC-1 and SUIT2 Clone 1 cells were incubated for 72 hours in the 
presence of variable concentrations of entinostat (0-50μM). Cells were then lysed and subjected to Western blotting using an antibody 
directed at acetylated histone H3 or total H3. The membrane was then probed for β-actin to confirm equal loading of lanes.
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doses of both drugs. Treatment with entinostat resulted 
in a dose-dependent increase in gemcitabine-induced 
inhibition of cell proliferation (Figure 3). This effect was 
observed in both gemcitabine-sensitive and gemcitabine 
resistant cell lines (see Supplementary Figure 1 for 
gemcitabine sensitivities).
Median dose-effect analysis over a range of 
gemcitabine and entinostat concentrations was undertaken 
to investigate whether the observed gemcitabine and 
entinostat interactions were antagonistic, additive or 
synergistic. Combination index (CI) values <, = or > 1 
indicate synergy, additive effect or antagonism, 
respectively. Combination treatment with gemcitabine and 
entinostat yielded CI values considerably <1, providing 
evidence that gemcitabine and entinostat were highly 
synergistic in all cell lines tested (Figure 4).
Entinostat enhances gemcitabine-induced 
apoptosis
Flow cytometry analysis of PANC-1 cells stained 
with annexin V-FITC and propidium iodide showed that 
gemcitabine-induced apoptosis was also significantly 
increased in the presence of entinostat (Figure 5). 
Furthermore, compared to entinostat alone, treatment with 
both drugs resulted in more rapid apoptosis, with a three-
fold increase in cells in late phase apoptosis following 
combination treatment.
Using a haploid genetic screen to identify 
potential predictive biomarkers of resistance to 
combination treatment with gemcitabine and 
entinostat
To identify genes involved in resistance to toxic 
doses of combination treatment with gemcitabine and 
entinostat, we performed a genome-wide loss-of-function 
screen in a derivative of the KBM7 chronic myeloid 
leukaemia cell line which is haploid for all chromosomes 
except chromosome 8. KBM7 cells were mutagenized 
using a gene trap retrovirus to produce a library of cells 
with inactivating insertions in non-essential genes [2, 3]. 
Approximately 100 million gene-trap mutagenised KBM7 
cells were then exposed to gemcitabine and entinostat 
or entinostat alone for 21 days, after which surviving, 
resistant cells were expanded and insertions were mapped 
and aligned to the human genome. Treatment with 
gemcitabine alone failed to induce near-complete cell 
death after 72 hours thus this was not taken forward for 
sequencing.
Deoxycytidine kinase (DCK) ranked as one of the 
genes with the highest degree of insertional enrichment in 
terms of both number of independent insertions and total 
number of insertions following combination treatment (but 
not following entinostat treatment alone) (Figure 6 and 
Supplementary Table 1); 6 independent insertions were 
identified, 3 of which had insert counts of 9384, 56450, 
and 404817 respectively, and which were significantly 
enriched compared to the unselected but mutagenized 
control cells (p<0.0001). As DCK is already known to be 
the rate-limiting activating enzyme for gemcitabine, we 
chose to validate this gene first. Immunoblotting for DCK 
protein in untreated mutagenized haploid KBM7 cells 
and in the expanded pools of resistant cells following 
combination drug treatment confirmed loss of protein 
expression in the resistant cells (Figure 7A).
As the KBM7 cells are of leukaemic origin and 
near-haploid genotype, representing a very specific cancer 
entity, we next validated whether DCK inactivation 
also causes resistance to gemcitabine and entinostat in 
pancreatic cancer cells. Although DCK was expressed 
in all the pancreatic cancer cell lines examined 
(Supplementary Figure 2), its expression level did not 
correlate with the cell line sensitivity to gemcitabine and 
entinostat. Using the CRISPR/Cas9 gene editing system, 
we inactivated DCK in PANC-1 and SUIT2 pancreatic 
cancer cells. Immunoblotting for DCK in wild type and 
DCK knockout PANC1 and SUIT2 cells confirmed loss 
of protein expression in both cell lines following CRISPR/
Cas9 targeted inactivation of DCK (Figure 7B). Wild type 
and DCK knockout PANC1 and SUIT2 cells were then 
treated with variable concentrations of entinostat (0-10μM) 
and gemcitabine (0-10μM) for 72 hours and cell viability 
was assessed by XTT assays. Inactivation of DCK in both 
cell lines resulted in resistance to gemcitabine alone and 
to combination treatment with gemcitabine and entinostat 
at all doses tested (Figure 7C and 7D).
DISCUSSION
The outcome for patients with pancreatic cancer 
is extremely poor. Whilst combination chemotherapy 
has recently shown improved outcomes, the significant 
additional toxicity limits their use and single agent 
gemcitabine chemotherapy remains the standard of care 
for many patients with advanced pancreatic cancer. 
The potent class I HDAC inhibitor, entinostat is orally 
bioavailable with an established safety profile both as a 
single agent and in combination with other drugs, making 
it an ideal agent for combination with other drugs [21, 
26–28]. We have identified gemcitabine and entinostat 
as a potential new combination therapy in pancreatic 
cancer, and in this proof-of-principle study we have 
demonstrated that a recently developed genome-wide 
loss-of-function screen can be used as a novel platform 
to identify the critical genes that determine resistance to 
cancer therapeutics.
We have shown that the potent class I HDAC 
inhibitor, entinostat, can reverse gemcitabine resistance in 
pancreatic cancer cell lines. Indeed, dynamic chromatin 
modifications have recently been identified as a novel 
non-mutational mechanism of drug resistance that can be 
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reversed by histone deacetylase (HDAC) inhibitors [11]. 
However, in our case the precise underlying mechanism 
of action currently remains unknown. We have shown that 
this is not through upregulation of DCK expression (data 
not shown), and as we validate other screening hits this 
may shed further light on a potential mechanism. The fact 
that synergistic effects were observed even when using 
minimally effective doses of entinostat is of additional 
Figure 3: Effect of gemcitabine and entinostat on cell proliferation. (A-F) PANC-1, MIA PaCa-2, BxPC-3, CFPAC-1, SUIT2 
and SUIT2 Clone 1 cells were plated at a density of 3-5 x103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated 
for 72 hours in the absence (blue column) or presence of gemcitabine (red column) or entinostat (green column), or the combination of 
gemcitabine plus entinostat (purple column). Cell viability was determined by XTT assays. The data are presented as mean inhibition 
rates from triplicate wells from three independent experiments ±SE. SUIT2 Clone 1 cells are gemcitabine-resistant cells derived from the 
parental SUIT2 cells. *** P <0.001.
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Figure 4: The median dose-effect method of Chau and Talalay and Compusyn software were used to examine the 
interaction between gemcitabine and entinostat in each cell line. (A) Summary table of all the combination index (CI) values 
obtained from the analysis and their interpretation. CI values < 1 indicates synergy, CI=1 indicates additive and CI values > 1 indicates 
antagonism between the two drugs. (B) The CI values are expressed graphically as normalised isobolograms.
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potential clinical value as more efficacious and well 
tolerated treatment currently represents an unmet need for 
patients with advanced pancreatic cancer.
We have also shown that entinostat synergistically 
enhances the cytotoxicity of gemcitabine in gemcitabine-
sensitive cell lines. Indeed it has previously been 
demonstrated that inhibition of HDAC activity can prevent 
acquired drug resistance [11]. The potential ability of 
HDAC inhibitors to prevent the development of drug 
resistance carries great appeal and could surmount current 
challenges of trying to overcome resistance by using a 
single rationally targeted agent, particularly as it is likely 
that multiple distinct mechanisms are involved in the 
setting of acquired drug resistance.
To optimally facilitate patient selection for this 
novel combination therapy, and to better understand 
the mechanism of action of gemcitabine and entinostat 
in combination, we performed a genome-wide genetic 
screen in haploid KBM7 cells. Deoxycytidine kinase 
(DCK) was identified as one of the critical genes in 
determining resistance to treatment with gemcitabine 
alone or in combination with entinostat. DCK is 
already known to be important in the metabolism of 
gemcitabine; it is the rate limiting enzyme responsible 
for conversion of gemcitabine prodrug to its active 
diphosphate and triphosphate metabolites. Deficiency 
of DCK activity has also been reported to be associated 
with gemcitabine resistance and pre-treatment levels 
have been correlated with overall survival following 
gemcitabine treatment [29–31]. Thus our finding 
demonstrates the ability of the haploid genetic screen 
to correctly identify genes that predict treatment 
resistance. Indeed, this haploid genetic screening 
approach has recently been successfully used to identify 
Figure 5: Induction of apoptosis. PANC-1 cells were treated with vehicle control, gemcitabine 10μM, entinostat 10μM or gemcitabine 
10μM plus entinostat 10μM for 72 hours, and then analyzed by flow cytometry to determine the percentage of cells displaying annexin V+ 
(early apoptosis) or annexin V+/ propidium iodide+ staining (late apoptosis).
Figure 6: Insertion sites in the DCK gene. Schematic outline of the unique gene-trap insertion sites (red lines) in the DCK gene in 
cells exposed to gemcitabine and entinostat. Grey boxes represent exons.
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the novel genes driving resistance to the topoisomerase 
II inhibitor, doxorubicin, and the Wee1 inhibitor, MK-
1775 [32–33]. The results from our and these recent 
studies highlights the potential clinical utility of this 
unbiased genome-wide genetic screen in helping to 
stratify patients for any cytotoxic or targeted therapy, 
and preventing patients receiving ineffective treatments 
(that are also associated with adverse side effects).
Figure 7: Validation of DCK from the haploid screen. (A) Western blot analysis of DCK protein expression in cell extracts 
from untreated gene-trap-mutagenised KBM7 cells and from the expanded pool of resistant gene trap-mutagenised KBM7 cells following 
treatment with gemcitabine (100nM) and entinostat (1μM for 3 days after which it was diluted to 100nM) for 21 days. (B) Western blot 
analysis of DCK protein expression in cell extracts from wild type and DCK knockout (KO) PANC-1 and SUIT2 cells, following CRISPR/
Cas9 targeted inactivation of DCK. (C and D) To assess the effect of DCK inactivation on cell proliferation (C) wild type (WT) and DCK 
knockout (KO) PANC-1 cells and (D) wild type and DCK KO SUIT2 cells were plated at a density of 4,000 per well in 96-well microtiter 
plates, allowed to adhere overnight and incubated for 72 hours with vehicle control, or gemcitabine (0.1μM) or entinostat (5 or 10μM) or 
the combination of gemcitabine plus entinostat. Cell viability was determined by XTT assays. The data are presented as mean inhibition 
rates from triplicate wells from three independent experiments ±SE. *** P < 0.001.
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A novel finding of our study is the critical 
importance of DCK for gemcitabine sensitivity and thus 
any combination therapy using gemcitabine; pancreatic 
cancer cells without DCK are resistant to gemcitabine 
alone or in combination with entinostat. Other genes 
known to be important for gemcitabine transport 
and metabolism were not identified in our screen, 
demonstrating one of the key advantages of this screen 
in only revealing those genes that are essential for drug 
response. Genetic mutations of DCK are not a common 
mechanism of resistance to intrinsic or acquired resistance 
to gemcitabine, and DCK mutations in patients with 
pancreatic cancer is actually uncommon, present in less 
than 5% of all tumours analysed [30, 34], but our finding, 
if validated, may prevent this group of patients from 
receiving a potentially ineffective treatment.
Pancreatic cancer is characterised by a dense 
desmoplastic reaction, composed of stromal and immune 
cells, which also contributes to chemotherapy resistance. 
We are currently validating other screening hits to generate 
a panel of treatment predicting factors that we will take 
forward for further in vivo validation using a genetically 
engineered mouse model that can recapitulate the human 
form of the disease.
In conclusion, we have identified gemcitabine and 
entinostat as a potential new combination therapy in 
pancreatic cancer, and in this proof-of-principle study we 
have demonstrated that a recently developed genome-wide 
haploid genetic screen can be used as a novel approach 
to identify the critical genes that determine treatment 
response. This approach, involving an initial screen in 
haploid cells, followed by in vitro and in vivo validation 
in disease-specific backgrounds, should be considered in 
the development of new anticancer therapies.
MATERIALS AND METHODS
Cell culture
Human pancreatic cancer cell lines PANC-1, MIA 
PaCa-2, BxPC-3, CFPAC-1, SUIT2 and SUIT2 Clone 1 
were kindly donated by Dr William Greenhalf (University 
of Liverpool). The SUIT2 clone 1 cells are a gemcitabine 
resistant clone generated in Liverpool from the parent 
SUIT2 cells; the remaining cell lines were purchased 
from the American Type Culture Collection (ATCC). 
All pancreatic cancer cell lines were cultured in RPMI 
1640 medium (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS), 2% L-glutamine and 1% penicillin-
streptomycin, at 37°C in 5% CO2.
The haploid KBM7 cells and gene-trap retroviral 
constructs were kindly donated by Dr Thijn R 
Brummelkamp (Netherlands Cancer Institute). KBM7 
cells and derivatives were grown in Iscove’s modified 
Dulbecco’s medium (IMDM) with 10% heat-inactivated 
FBS and 1% penicillin-streptomycin. Mutant KBM7 cells 
were prepared as described in detail by Carette et al [2].
Haploid cell screening
Haploid cell genetic screens with gemcitabine 
(Cambridge Bioscience) and entinostat (Cambridge 
Bioscience) were performed using 100 million 
mutagenized KBM7 cells, as previously described [2]. 
In brief, mutagenised haploid KBM7 cells were exposed 
to gemcitabine and entinostat or entinostat alone for 21 
days. For gemcitabine, a concentration of 0.1μM was used 
during the complete incubation period. For entinostat, a 
concentration of 1μM was used for 3 days followed by a 
dilution to 100nM for the remaining 18 days. Surviving 
clones were expanded and then pooled before genomic 
DNA extraction.
Mapping of insertion sites
Sequences flanking the retroviral insertion 
sites were amplified using an inverse PCR protocol 
as previously described followed by high throughput 
sequencing (Illumina HiSeq 2000). Reads from regions 
flanking the gene-traps were aligned to the human 
genome build 37 (hg19) using the Burrows-Wheeler 
Aligner. Only reads that aligned uniquely without 
mismatches were considered. The number of insertions 
in the sense orientation (ie inactivating mutations) 
per individual gene was calculated as well as the total 
number of insertions. Genes were ranked based on both 
the total number of insertions and the number of unique 
insertions.
Cell viability assays
3x103- 5x103 cells were seeded in 96-well microtitre 
plates and allowed to adhere overnight before adding 
indicated amounts of gemcitabine and/or entinostat. After 
3 days of treatment, cell viability was measured using the 
XTT colorimetric assay (Roche and Promega) according 
to the manufacturer’s protocol. Viability was plotted 
as percentage viability compared to untreated control. 
Results were calculated from at least two independent 
experiments with triplicates each time, and all data are 
presented as means +/- SE. Student’s t-tests for paired data 
were employed and considered as significant as follows: 
*P < 0.05; **P < 0.01; and ***P < 0.001.
For each of the experiments, the extent and direction 
of antitumour interactions between gemcitabine and 
entinostat were determined by calculating combination 
index (CI) using the median dose–effect method of Chau 
and Talalay, and CompuSyn software. CI <1, CI = 1, CI >1 
indicates synergistic, additive or antagonistic effects 
respectively [23–25].
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Apoptosis
7.5x105 cells were seeded in 24-well plates and 
allowed to adhere overnight before adding indicated 
amounts of gemcitabine and/or entinostat. After 72 hours 
cells were harvested and stained for annexin V (early 
apoptosis marker) and propidium iodide (PI) (late 
apoptosis) using the Annexin V kit (Sigma-Aldrich) 
according to the manufacturer’s protocol followed by flow 
cytometric analysis.
Western blot analysis
Cells were washed and lysed in RIPA protein 
lysis buffer containing a complete protease inhibitor 
cocktail (Roche). Proteins were then separated using 
SDS-polyacryamide gel electrophoresis, transferred 
to nitrocellulose membranes and incubated with the 
indicated primary antibodies: DCK (Abcam ab186128), 
acetylated histone H3 (Cell Signalling #4353), histone H3 
(Cell Signalling #4499), calreticulin (Abcam ab2907) and 
β-actin (Abcam ab8229).
CRISPR/Cas-9
1.5 x 105 SUIT2 or PANC-1 cells were seeded in 
6-well plates and allowed to adhere overnight before 
adding 300μl transfection medium (Santa-Cruz) containing 
3μl CRISPR Transfection Reagent (Santa-Cruz) and 2μg 
of control (Santa Cruz - sc-418922) or DCK CRISPR 
plasmid (Santa-Cruz - sc-417715). 24 hours following 
transfection, GFP positive cells were isolated by flow 
cytometry and cultured in DMEM media containing 20% 
FCS. Following recovery, cells were maintained under 
normal culture conditions and protein and cell viability 
assays performed as described above.
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